T-Therapeutics raises $133M Series B for T-cell engager push
- UK-based T-Therapeutics closed a $133M Series B co-led by Advent Life Sciences and the British Business Bank.
- Eli Lilly, J&J's venture arm, Samsara BioCapital and Sofinnova also joined; a $32M Series A extension came last year.
- Its platform uses fully human T-cell receptors to build bispecific T-cell engagers against intracellular targets.
- Lead candidates TTX-008 (cancer) and TTX-018 (autoimmune) are preclinical; funds will go to proof-of-concept data.
💡 Points Based on public reports
A $133M round for a preclinical company is a bet on the platform, not the assets. TCR-based engagers reach intracellular targets that antibody-based T-cell engagers can't, which is the real differentiator in a crowded bispecific field. Lilly and J&J's venture arm on the cap table read as option-building, and splitting oncology and autoimmune keeps the partnering menu wide.
T-Therapeutics reloads with a $133M megaround for bispecifics ↗